Discontinued Product

(±)-HA-966 (Cat. No. 0198) has been withdrawn from sale for commercial reasons.
Description: Partial NMDA agonist, acts glycine site
Chemical Name: (RS)-3-Amino-1-hydroxypyrrolidin-2-one
Literature (5)

Biological Activity for (±)-HA-966

The overall effect of this much-investigated compound is the result of the actions of the two enantiomers: glycine-NMDA antagonism by the (+)-isomer and sedative and ataxic effects of the (-)-isomer. See separate isomers 0281 and 0282.

Technical Data for (±)-HA-966

M. Wt 116.12
Storage Store at RT
CAS Number 1003-51-6

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (±)-HA-966

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for (±)-HA-966

References are publications that support the biological activity of the product.

Evans et al (1978) Mg2+-like selective antagonism of excitatory amino acid - induced responses by α,ε-diaminopimelic acid, D-α-aminoadipate and HA-966 in isolated spinal cord of frog and immature rat. Brain Res. 148 536 PMID: 207392

Foster and Kem (1989) HA-966 antagonises NMDA receptors through a selective interaction with the glycine modulatory site. J.Neurosci. 9 2191 PMID: 2542488

Lodge (1989) Non-competitive NMDA antagonists. The NMDA Receptor (2nd edition). Eds. G.L.Collingr 37

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Agonists

Keywords: (±)-HA-966, (±)-HA-966 supplier, NMDA, Receptors, 0198, Tocris Bioscience

Citations for (±)-HA-966

Citations are publications that use Tocris products.

Currently there are no citations for (±)-HA-966.

Reviews for (±)-HA-966

There are currently no reviews for this product. Be the first to review (±)-HA-966 and earn rewards!

Have you used (±)-HA-966?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.